市場洞察レポート:中国革新薬企業のグローバル展開加速と今後の展望

Market Insights Report: Accelerating Global Expansion of Chinese Innovative Pharmaceutical Companies and Future Outlook

overview

This report analyzes the activities of three innovative Chinese pharmaceutical companies, Hutchison MediPharma, Haihe Biopharma, and Ascentage Pharma, and examines their global expansion strategies and future prospects. These companies are increasing their presence in the international market through their unique technological capabilities and strategic alliances, suggesting that innovative drugs from China are beginning to be competitive in the global market.

Cafes Japan

Trends of each company

  • WuHuang Pharmaceuticals: Successful global expansion of Futinib and its commercialization strategy

    Wuhuang Medical has successfully developed an innovative anticancer drug called Futinib and is accelerating its global expansion through a partnership with Takeda Pharmaceutical Co., Ltd. In January 2023, the company signed an agreement to license the overseas development and commercialization rights of Futinib to Takeda Pharmaceutical Co., Ltd., receiving an upfront payment of US$400 million and a total of US$1.13 billion.

    Futinib has been approved for third-line CRC treatment in the US, EU and Japan since November 2023, and was launched in Japan in September 2024. This is the first innovative drug from Shanghai to be approved in the US, Japan and Europe, symbolizing the improvement of China's drug development capabilities. It has also achieved commercial success, with global sales exceeding US$200 million by October 31, 2024 and milestone payments from Takeda Pharmaceutical.

    Wehuang Medical's business strategy is to focus on the research and development of best-in-class small molecule innovative drugs and differentiate itself by choosing the most suitable development path. We are also strengthening our in-house commercialization team, aiming to evolve from a biotechnology company to a biopharmaceutical company. Furthermore, we are accelerating sales in overseas markets through licensing-out agreements with multiple MNCs.

    Official website: Heji Huangpu Medical (Shanghai) Co., Ltd.

    Cafes Japan
  • Kaiwa Pharmaceuticals: Gumetinib Approval in Japan and International Development Strategy

    Kaiwa Pharmaceuticals has successfully developed an innovative anti-cancer drug called gumetinib and entered the Japanese market through a partnership with Taiho Pharmaceutical Co., Ltd. In February 2024, the two companies signed an exclusive license agreement for the development, manufacturing and commercialization of gumetinib in Japan, Asia (excluding China) and Oceania.

    Gumetinib was officially approved in Japan in June 2024, becoming the first innovative drug developed primarily by a Chinese company to be approved in Japan. This demonstrates the success of Kaihe Pharmaceutical's international development strategy, and is expected to be expanded into the Asian region in the future.

    As a drug research and development company led by an academician of the Chinese Academy of Engineering, Haihe Pharmaceutical attaches great importance to independent innovation and has a R&D and management team with a global perspective, actively engaging in the international development of innovative drugs.

    Official website: Shanghai Haiwa Vegetable Research Development Co., Ltd.

 

Cafes Japan
  • Yasin Pharmaceutical: Global expansion of orevatinib and partnership strategy

    Yasheng Medical has successfully developed an innovative anti-cancer drug called orevatinib and is exploring the possibility of global expansion through a collaboration with Takeda Pharmaceutical Co., Ltd. In June 2024, the company signed an exclusive option agreement with Takeda Pharmaceutical Co., Ltd. regarding orevatinib. If the option right is exercised, Takeda Pharmaceutical Co., Ltd. will obtain exclusive rights to develop and commercialize orevatinib globally (excluding mainland China, Hong Kong SAR, Macau SAR, Taiwan, and Russia).

    Orevatinib is expected to achieve sales of RMB 241 million in 2024, a 52% increase over the previous year, and is continuing to grow. In November 2024, a new indication was listed in the National Pharmaceutical Insurance Catalog, and sales within China are also expanding.

    Yashen Medical is committed to researching and developing original innovative drugs with global first-in-class or best-in-class potential, and has implemented a global innovation strategy. It has established global collaborations with major biopharmaceutical companies such as Takeda Pharmaceutical, Merck, AstraZeneca and Pfizer, as well as academic institutions such as Mayo Clinic and Dana-Farber Cancer Institute, to accelerate global development.

    Official website: Yusheng Medical School

Future outlook

With government support and independent technological capabilities, China's innovative pharmaceutical companies are strengthening their presence in the global market. It is expected that more innovative drugs will be developed and China will become more competitive in the international market.

These companies are expected to accelerate their global expansion through strategic alliances and build their own sales networks to achieve further growth, while the expansion of the Chinese domestic market will also be a driving force behind their growth.

Conclusion

Chinese innovative pharmaceutical companies are becoming important players in the global market. By closely monitoring their activities and analyzing their future growth strategies, we can grasp the new trends in the pharmaceutical market.

Back to blog